FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165069471> ?p ?o ?g. }

• W3165069471 abstract "Abstract Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3 days vs. placebo in non-hospitalized COVID-19 patients. RT-PCR from a nasopharyngeal swab was obtained at recruitment and then every two days. Primary endpoint was reduction of viral-load on the 6 th day (third day after termination of treatment) as reflected by Ct level>30 (non-infectious level). The primary outcome was supported by determination of viral culture viability. Results Eighty-nine patients were eligible (47 in ivermectin and 42 in placebo arm). Their median age was 35 years. Females accounted for 21·6%, and 16·8% were asymptomatic at recruitment. Median time from symptom onset was 4 days. There were no statistical differences in these parameters between the two groups. On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31). In a multivariable logistic-regression model, the odds of a negative test at day 6 was 2.62 time higher in the ivermectin group (95% CI: 1·06–6·45). Cultures at days 2 to 6 were positive in 3/23 (13·0%) of ivermectin samples vs. 14/29 (48·2%) in the placebo group (p=0·008). Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients. The study is registered at ClinicalTrials.gov NCT 044297411." @default.
• W3165069471 created "2021-06-07" @default.
• W3165069471 creator A5008056416 @default.
• W3165069471 creator A5011932805 @default.
• W3165069471 creator A5021617266 @default.
• W3165069471 creator A5047670179 @default.
• W3165069471 creator A5048930117 @default.
• W3165069471 creator A5050323834 @default.
• W3165069471 creator A5055918792 @default.
• W3165069471 creator A5058920753 @default.
• W3165069471 creator A5082698302 @default.
• W3165069471 creator A5090111671 @default.
• W3165069471 date "2021-05-31" @default.
• W3165069471 modified "2023-09-26" @default.
• W3165069471 title "Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial" @default.
• W3165069471 cites W1965936780 @default.
• W3165069471 cites W1977475475 @default.
• W3165069471 cites W1991249533 @default.
• W3165069471 cites W2014301459 @default.
• W3165069471 cites W2033241349 @default.
• W3165069471 cites W2324097903 @default.
• W3165069471 cites W2593557252 @default.
• W3165069471 cites W2985554306 @default.
• W3165069471 cites W3008028633 @default.
• W3165069471 cites W3009301311 @default.
• W3165069471 cites W3012421327 @default.
• W3165069471 cites W3013893137 @default.
• W3165069471 cites W3014962324 @default.
• W3165069471 cites W3016868609 @default.
• W3165069471 cites W3026711303 @default.
• W3165069471 cites W3027829318 @default.
• W3165069471 cites W3034282486 @default.
• W3165069471 cites W3035855865 @default.
• W3165069471 cites W3086865863 @default.
• W3165069471 cites W3107056972 @default.
• W3165069471 cites W3111068209 @default.
• W3165069471 cites W3120108340 @default.
• W3165069471 cites W3127806990 @default.
• W3165069471 cites W3135420706 @default.
• W3165069471 doi "https://doi.org/10.1101/2021.05.31.21258081" @default.
• W3165069471 hasPublicationYear "2021" @default.
• W3165069471 type Work @default.
• W3165069471 sameAs 3165069471 @default.
• W3165069471 citedByCount "10" @default.
• W3165069471 countsByYear W31650694712021 @default.
• W3165069471 countsByYear W31650694712022 @default.
• W3165069471 countsByYear W31650694712023 @default.
• W3165069471 crossrefType "posted-content" @default.
• W3165069471 hasAuthorship W3165069471A5008056416 @default.
• W3165069471 hasAuthorship W3165069471A5011932805 @default.
• W3165069471 hasAuthorship W3165069471A5021617266 @default.
• W3165069471 hasAuthorship W3165069471A5047670179 @default.
• W3165069471 hasAuthorship W3165069471A5048930117 @default.
• W3165069471 hasAuthorship W3165069471A5050323834 @default.
• W3165069471 hasAuthorship W3165069471A5055918792 @default.
• W3165069471 hasAuthorship W3165069471A5058920753 @default.
• W3165069471 hasAuthorship W3165069471A5082698302 @default.
• W3165069471 hasAuthorship W3165069471A5090111671 @default.
• W3165069471 hasBestOaLocation W31650694711 @default.
• W3165069471 hasConcept C126322002 @default.
• W3165069471 hasConcept C141071460 @default.
• W3165069471 hasConcept C142462285 @default.
• W3165069471 hasConcept C142724271 @default.
• W3165069471 hasConcept C156957248 @default.
• W3165069471 hasConcept C168563851 @default.
• W3165069471 hasConcept C203014093 @default.
• W3165069471 hasConcept C203092338 @default.
• W3165069471 hasConcept C204787440 @default.
• W3165069471 hasConcept C27081682 @default.
• W3165069471 hasConcept C2777499811 @default.
• W3165069471 hasConcept C2777910003 @default.
• W3165069471 hasConcept C3013748606 @default.
• W3165069471 hasConcept C42972112 @default.
• W3165069471 hasConcept C71924100 @default.
• W3165069471 hasConcept C90924648 @default.
• W3165069471 hasConceptScore W3165069471C126322002 @default.
• W3165069471 hasConceptScore W3165069471C141071460 @default.
• W3165069471 hasConceptScore W3165069471C142462285 @default.
• W3165069471 hasConceptScore W3165069471C142724271 @default.
• W3165069471 hasConceptScore W3165069471C156957248 @default.
• W3165069471 hasConceptScore W3165069471C168563851 @default.
• W3165069471 hasConceptScore W3165069471C203014093 @default.
• W3165069471 hasConceptScore W3165069471C203092338 @default.
• W3165069471 hasConceptScore W3165069471C204787440 @default.
• W3165069471 hasConceptScore W3165069471C27081682 @default.
• W3165069471 hasConceptScore W3165069471C2777499811 @default.
• W3165069471 hasConceptScore W3165069471C2777910003 @default.
• W3165069471 hasConceptScore W3165069471C3013748606 @default.
• W3165069471 hasConceptScore W3165069471C42972112 @default.
• W3165069471 hasConceptScore W3165069471C71924100 @default.
• W3165069471 hasConceptScore W3165069471C90924648 @default.
• W3165069471 hasLocation W31650694711 @default.
• W3165069471 hasOpenAccess W3165069471 @default.
• W3165069471 hasPrimaryLocation W31650694711 @default.
• W3165069471 hasRelatedWork W1995188757 @default.
• W3165069471 hasRelatedWork W2016679923 @default.
• W3165069471 hasRelatedWork W2113780394 @default.
• W3165069471 hasRelatedWork W2116001782 @default.
• W3165069471 hasRelatedWork W3165069471 @default.
• W3165069471 hasRelatedWork W3194652165 @default.

• next